

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

GRANT OF OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort NeuroScientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on November 20, 2025, the Company has resolved to grant share options (the “**Options**”) to Dr. Will Zhang, R&D Senior Director of Brain-Computer Interface (BCI) Technologies and Chief Researcher of Chaos Brain-Computer Research Institute of the Group (the “**Grantee**”), to subscribe for up to an aggregate of 500,000 ordinary shares of the Company of US\$0.00002 each (the “**Shares**”) in the capital of the Company pursuant to the share scheme (the “**Share Scheme**”) adopted by the Company on July 12, 2023, subject to the acceptance of the Grantee. Dr. Will Zhang is primarily responsible for encompassing BCI hardware system development, software algorithm design and electrode technology innovation in the Group. Dr. Will Zhang possesses extensive expertise in electrical engineering and implantable medical devices product development, and nearly two decades of substantial experience across multiple multinational corporations. Before joining the Group, Dr. Will Zhang previously worked at Abbott Laboratories, Baylor College of Medicine and Medtronic Inc., where he contributed to the technology development and testing of electrical engineering for implantable neuromodulation products.

Details of the Options are as follows:

Date of Grant	November 20, 2025 (the “ Date of Grant ”)
Number of Grantees	One Grantee (employee of the Group)

Exercise price of the Options granted	HK\$11.302 per Share, representing the highest of: (i) the closing price of HK\$10.400 per Share as stated in the daily quotation's sheet issued by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on the Date of Grant; (ii) the average closing price of HK\$11.302 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of US\$0.00002
Number of Options granted	An aggregate of 500,000 Options, all of which were granted to one employee of the Group (each Option shall entitle the holder of the Option to subscribe for one Share)
Validity period of the Options	Ten (10) years from the Date of Grant
Vesting period of the Options	The Options shall be vested in five (5) years, 20% of which shall be vested on each anniversary of the Date of Grant.
Performance targets	The vesting of the Options is not subject to any performance targets. The purpose of the Share Scheme is to provide incentive to eligible participants in order to promote the development and success of the business of the Group. The Options to be granted will give the Grantee an opportunity to have a personal stake in the Company and will help motivate the Grantee in optimizing their performance and efficiency. The number of Options to be granted are based on the work performance and potential of the Grantee and no additional performance target is imposed before the Options are vested to the Grantee. In view of the above, the remuneration committee of the Company (the "Remuneration Committee") considered the grant of Options aligned with the purpose of the Share Scheme.

Clawback mechanism	The Options granted will be subject to the clawback mechanism as set out in the Share Scheme and offer letter of the grant of Options as determined by the Board, in particular, the lapse of Options upon cessation of employment of the Grantee and the cancellation of Options at the discretion of the Board.
--------------------	---

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries: (i) no financial assistance has been provided by the Group to the Grantee for the purchase of shares under the Share Scheme; (ii) the Grantee is not a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (iii) the Grantee is not a related entity participant or service provider (as defined under the Listing Rules); and (iv) the Grantee is not a participant with options and awards granted and to be granted exceeding the 1% individual limit under the Listing Rules.

Subsequent to the grant of Options, the number of Shares available for future grants pursuant to the Share Scheme is 50,255,510 Shares and, among which, the number of Shares available for future grant under the service provider limit of the Share Scheme is 5,826,581 Shares.

By order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, November 20, 2025

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; and Dr. Zhang Haixiao, Mr. Fan Xin and Mr. Li Zhiyong as the independent non-executive directors.